Advertisement

Topics

Janssen Enters into Collab with Theravance Biopharma for Oral Drug Candidate for Inflammatory Bowel Disease

11:58 EST 7 Feb 2018 | Drug Discovery Development

The Janssen Pharmaceutical Companies of Johnson & Johnson announced their entry into a worldwide collaboration with an affiliate of Theravance Biopharma, Inc. to develop TD-1473, a first-in-class oral, gastrointestinal (GI) restricted pan-Janus kinase (JAK) inhibitor for the treatment of inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis (UC).
Contributed Author: 
Janssen
Topics: 

Original Article: Janssen Enters into Collab with Theravance Biopharma for Oral Drug Candidate for Inflammatory Bowel Disease

NEXT ARTICLE

More From BioPortfolio on "Janssen Enters into Collab with Theravance Biopharma for Oral Drug Candidate for Inflammatory Bowel Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...